Pharmacists' Participation in the Treatment of a Patient with Complicated Abdominal Infection Secondary to Invasive Fungal Infection

doi:10.19803/j.1672-8629.2020.02.08

Abstract

Abstract: Objective To investigate the role of clinical pharmacists in the medication of a patient with complicated intra-abdominal infection after gastrointestinal surgery. Methods By participating in the medication of a patient with complicated abdominal infection secondary to invasive fungal infection, clinical pharmacists were able to find the causes of acute kidney injury of the patient and adjusted the dosage of vancomycin immediately according to the result of treatment with vancomycin. Then, these clinical pharmacists suggested adjusting the therapeutic regimen after comparing the pharmacodynamics and pharmacokinetics of such antifungal agents as triazole, echinocandins and polyene in line with the latest guidelines before the clinicians took the advice. Results After seven days of treatment with this regimen, the blood culture of the patient was negative, so clinical pharmacists suggested that the patient be returned to an ordinary ward for further treatment. Conclusion Clinical pharmacists can assist clinicians in adjusting the drug regimen and improve the level of clinical medication by making full use of their knowledge of pharmacy.

Key words: complicated intra-abdominal infection, invasive fungal infection, clinical pharmacist, pharmaceutical care

CLC Number:

R915

ZHOU Ran, CHEN Zhangzhang. Pharmacists' Participation in the Treatment of a Patient with Complicated Abdominal Infection Secondary to Invasive Fungal Infection[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 106-110.

References

[1] 任建安. 复杂腹腔感染诊断与治疗策略[J]. 中国实用外科杂志,2011,31(9):871-873.
[2] Filippone E J,Kraft W K,Farber J L.The Nephrotoxicity of Vancomycin[J]. Clin Pharmacol Ther,2017,102(3):459-469.
[3] Chuma M,Makishima M,Imai T,et al.Relationship between initial vancomycin trough levels and early-onset vancomycinassociated nephrotoxicity in critically ill patients[J]. Ther Drug Monit, 2018,40(1):109-114.
[4] 马雪,蒋刚,蒋倩,等. 重症感染肿瘤患者使用万古霉素致相关肾功能不全的危险因素分析[J]. 中国医院药学杂志,2016,36(8):647-650.
[5] Dong M H,Wang J W,Wu Y,et al.Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China[J]. Int J Infect Dis,2015,37:125-128.
[6] Hanrahan T P,Harlow G,Hutchinson J,et al.Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis[J]. Crit Care Med,2014,42(12):2527-2536.
[7] 翟所迪,贺蓓,王睿,等.《中国万古霉素治疗药物监测指南》解读[J]. 中国临床药理学杂志,2016,32(17):1633-1636.
[8] 万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志,2012,30(11):641-646.
[9] 陈佰义,管向东,何礼贤,等. 万古霉素临床应用中国专家共识(2011版)[J]. 中国新药与临床杂志,2011,30(8):561-572.
[10] 刘智博,曹彬. 侵袭性念珠菌病的初始治疗:棘白菌素还是氟康唑[J]. 中华内科杂志,2017,56(10):774-776.
[11] De Pauw B,Walsh T J,Donnelly J P,et al.Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis,2008,46(12):1813-1821.
[12] 王小红,刘鹏,曹先伟. ERG11和ERG3基因突变与念珠菌对氟康唑耐药的关系[J]. 中国皮肤性病学杂志,2018,32(4):387-390.
[13] Pfaller M A,Messer S A,Hollis R J,et al.Variation in suscepti-bility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007[J]. J Clin Microbiol,2009,47(10):3185-3190.
[14] Cornely O A,Bassetti M,Calandra T,et al.ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients[J]. Clin Microbiol Infect,2012,18(7):19-37.
[15] Pappas P G,Kauffman C A,Andes D R,et al.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016,62(4):e1-50.
[16] Reboli A C,Rotstein C,Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis[J]. N Engl J Med,2007,356(24):2472-2482.
[17] Andes D R,Safdar N,Baddley J W,et al.Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials[J]. Clin Infect Dis,2012,54(8):1110-1122.
[18] Kuse E R,Chetchotisakd P,da Cunha C A,et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial[J]. Lancet,2007,369(9572):1519-1527.
[19] Mazuski J E,Tessier J,May A K,et al.The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection[J]. Surg Infect,2017,18(1):1-76.
[20] 白向荣,褚燕琦. 临床药师在干预万古霉素血药浓度监测的作用研究[J]. 中国药物警戒,2015,12(7):439-443.